EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
CA3162352A1
(en)
|
2010-10-01 |
2012-04-05 |
Modernatx, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
DE12722942T1
(en)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
PT3682905T
(en)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
LT2791160T
(en)
|
2011-12-16 |
2022-06-10 |
Modernatx, Inc. |
Modified mrna compositions
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
KR102186497B1
(en)
|
2012-03-27 |
2020-12-04 |
큐어백 아게 |
Artificial nucleic acid molecules
|
RU2660565C2
(en)
|
2012-03-27 |
2018-07-06 |
Кьюрвак Аг |
Artificial nucleic acid molecules comprising 5'top utr
|
CA2859452C
(en)
|
2012-03-27 |
2021-12-21 |
Curevac Gmbh |
Artificial nucleic acid molecules for improved protein or peptide expression
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
CA2868996A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
PL2922554T3
(en)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Terminally modified rna
|
AU2014220957A1
(en)
|
2013-02-22 |
2015-07-30 |
Curevac Ag |
Combination of vaccination and inhibition of the PD-1 pathway
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
BR112016001192A2
(en)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
VACCINE AGAINST ANGER
|
EP3450561A1
(en)
|
2013-08-21 |
2019-03-06 |
CureVac AG |
Method for increasing expression of rna-encoded proteins
|
SG10201801431TA
(en)
|
2013-08-21 |
2018-04-27 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
SG10201801428RA
(en)
*
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
WO2015024669A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Combination vaccine
|
EP3586871A3
(en)
|
2013-08-21 |
2020-03-11 |
CureVac AG |
Respiratory syncytial virus (rsv) vaccine
|
EP4043032A1
(en)
|
2013-08-21 |
2022-08-17 |
CureVac AG |
Rabies vaccine
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
JP2016538829A
(en)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
Polynucleotide encoding low density lipoprotein receptor
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
EP3415629A1
(en)
*
|
2013-12-30 |
2018-12-19 |
CureVac AG |
Artificial nucleic acid molecules
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
DK3090053T3
(en)
*
|
2013-12-30 |
2019-02-25 |
Curevac Ag |
Artificial nucleic acid molecules
|
WO2015101415A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
EP3842537A1
(en)
|
2013-12-30 |
2021-06-30 |
CureVac AG |
Artificial nucleic acid molecules
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
EP3129050A2
(en)
|
2014-04-01 |
2017-02-15 |
CureVac AG |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
KR102459599B1
(en)
|
2014-06-10 |
2022-10-26 |
큐어백 리얼 이스테이트 게엠베하 |
Methods and Means for enhancing RNA production
|
CA3179824A1
(en)
|
2014-06-25 |
2015-12-30 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US11149278B2
(en)
*
|
2014-12-12 |
2021-10-19 |
Curevac Ag |
Artificial nucleic acid molecules for improved protein expression
|
WO2016097065A1
(en)
*
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
SG10201906673WA
(en)
*
|
2014-12-30 |
2019-09-27 |
Curevac Ag |
Artificial nucleic acid molecules
|
EP3283059B1
(en)
|
2015-04-13 |
2024-01-03 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
EP3283125B1
(en)
|
2015-04-17 |
2021-12-29 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
BR112017018368B1
(en)
|
2015-04-22 |
2022-08-02 |
Curevac Ag |
COMPOSITION CONTAINING RNA FOR USE IN THE TREATMENT OR PROPHYLAXIS OF TUMOR AND/OR CANCER DISEASES, AND USE OF AN RNA FOR THE PREPARATION OF THE COMPOSITION
|
US11384375B2
(en)
|
2015-04-30 |
2022-07-12 |
Curevac Ag |
Immobilized poly(n)polymerase
|
DK3294885T3
(en)
|
2015-05-08 |
2020-08-10 |
Curevac Real Estate Gmbh |
METHOD OF PREPARING RNA
|
US11559570B2
(en)
*
|
2015-05-15 |
2023-01-24 |
CureVac SE |
Prime-boost regimens involving administration of at least one mRNA construct
|
SG10201910431RA
(en)
|
2015-05-20 |
2020-01-30 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
CN107530448A
(en)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
Include long-chain RNA dry powder composite
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
US10760070B2
(en)
|
2015-05-29 |
2020-09-01 |
Curevac Real Estate Gmbh |
Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
|
CA2990202A1
(en)
|
2015-06-29 |
2017-01-05 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
DK3112469T3
(en)
|
2015-06-30 |
2018-05-07 |
Ethris Gmbh |
EXPRESSIONS TO INCREASE THE TRANSLATION EFFECTIVENESS OF RNA MOLECULES
|
US20190017100A1
(en)
|
2015-07-01 |
2019-01-17 |
Curevac Ag |
Method for analysis of an rna molecule
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
US20190119357A1
(en)
*
|
2015-07-23 |
2019-04-25 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
US20200085852A1
(en)
*
|
2015-08-05 |
2020-03-19 |
Curevac Ag |
Epidermal mrna vaccine
|
MX2018001040A
(en)
|
2015-08-28 |
2018-06-15 |
Curevac Ag |
Artificial nucleic acid molecules.
|
AU2016324310B2
(en)
|
2015-09-17 |
2021-04-08 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
US10849920B2
(en)
|
2015-10-05 |
2020-12-01 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
EP3362576A1
(en)
|
2015-10-12 |
2018-08-22 |
CureVac AG |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
US20190218546A1
(en)
|
2015-10-16 |
2019-07-18 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
US20190225644A1
(en)
|
2015-10-16 |
2019-07-25 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
EP3373965A1
(en)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus vaccines
|
CN108778236A
(en)
*
|
2015-12-03 |
2018-11-09 |
Dna精华股份有限公司 |
Oligonucleotides in food, beverage, cosmetics and pharmaceutical preparation
|
DK3319622T3
(en)
|
2015-12-22 |
2020-05-04 |
Curevac Ag |
PROCEDURE FOR PREPARING RNA MOLECULE COMPOSITIONS
|
DK3394030T3
(en)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR RELEASE OF FUNDS
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
CN109104870B
(en)
|
2016-01-15 |
2021-10-15 |
丁恩雨 |
Universal nucleic acid drug carrier capable of enhancing mRNA stability and translatability
|
US20210180106A1
(en)
|
2016-02-12 |
2021-06-17 |
Curevac Ag |
Method for analyzing rna
|
US11723967B2
(en)
*
|
2016-02-17 |
2023-08-15 |
CureVac SE |
Zika virus vaccine
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
EP3445392A1
(en)
|
2016-04-22 |
2019-02-27 |
CureVac AG |
Rna encoding a tumor antigen
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
WO2017191258A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Influenza mrna vaccines
|
EP3452493A1
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Nucleic acid molecules and uses thereof
|
US20190336608A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
WO2017212006A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
US11478552B2
(en)
|
2016-06-09 |
2022-10-25 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
EP3468537A1
(en)
|
2016-06-14 |
2019-04-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
EP3500295A2
(en)
|
2016-08-19 |
2019-06-26 |
CureVac AG |
Rna for cancer therapy
|
BR112019008481A2
(en)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
LIPID NANOPARTICLE MRNA VACCINES
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
US11279923B2
(en)
|
2016-11-28 |
2022-03-22 |
Curevac Ag |
Method for purifying RNA
|
CN110177544A
(en)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
For delivering the excretion body of therapeutic agent
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
CN110582304A
(en)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
RNA for treating or preventing liver disease
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
CN108456669B
(en)
*
|
2017-02-20 |
2023-08-08 |
上海凯赛生物技术股份有限公司 |
Ribosome binding site, recombinant expression plasmid, transformant and application thereof
|
HUE060693T2
(en)
|
2017-03-15 |
2023-04-28 |
Modernatx Inc |
Compound and compositions for intracellular delivery of therapeutic agents
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
US20200085944A1
(en)
|
2017-03-17 |
2020-03-19 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
SG10202110491PA
(en)
*
|
2017-03-24 |
2021-11-29 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
AU2018256877B2
(en)
|
2017-04-28 |
2022-06-02 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
WO2018237066A1
(en)
*
|
2017-06-20 |
2018-12-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
|
JP2020530980A
(en)
|
2017-07-04 |
2020-11-05 |
キュアバック アーゲー |
New nucleic acid molecule
|
JP7355731B2
(en)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
Lipids for use in lipid nanoparticle formulations
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
WO2019036638A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
Methods of preparing modified rna
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
JP7275111B2
(en)
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
Method for producing lipid nanoparticles
|
RU2020115287A
(en)
*
|
2017-10-19 |
2021-11-19 |
Куревак Аг |
NEW MOLECULES OF ARTIFICIAL NUCLEIC ACIDS
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
US11525158B2
(en)
|
2017-12-21 |
2022-12-13 |
CureVac SE |
Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
CN112292395A
(en)
|
2018-04-17 |
2021-01-29 |
库瑞瓦格股份公司 |
Novel RSV RNA molecules and compositions for vaccination
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
JP2022501367A
(en)
|
2018-09-20 |
2022-01-06 |
モデルナティエックス インコーポレイテッドModernaTX, Inc. |
Preparation of lipid nanoparticles and method for administration thereof
|
CN113453707A
(en)
|
2018-12-21 |
2021-09-28 |
库瑞瓦格股份公司 |
RNA for malaria vaccine
|
KR20210135494A
(en)
|
2019-01-31 |
2021-11-15 |
모더나티엑스, 인크. |
Method for preparing lipid nanoparticles
|
JP2022523117A
(en)
|
2019-01-31 |
2022-04-21 |
モデルナティエックス インコーポレイテッド |
Vortex mixers and related methods, systems, and equipment
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
CN109971786B
(en)
*
|
2019-04-19 |
2022-09-23 |
上海市东方医院(同济大学附属东方医院) |
Nucleopore protein Nup54, vector thereof and application of recombinant adenovirus
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
CN112190591B
(en)
*
|
2019-07-08 |
2021-12-17 |
中国农业科学院兰州兽医研究所 |
Use of ribosomal protein RPL13 inhibitor for the preparation of a medicament for inhibiting IRES-dependent translation of viral replication
|
CN111041099B
(en)
*
|
2019-07-22 |
2021-09-17 |
江苏医药职业学院 |
Application of reagent for detecting expression level of G protein-coupled receptor 137B and kit
|
WO2021028439A1
(en)
|
2019-08-14 |
2021-02-18 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
IL292297A
(en)
|
2019-10-17 |
2022-06-01 |
Stridebio Inc |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
CN112980877A
(en)
*
|
2019-12-12 |
2021-06-18 |
中国科学院大连化学物理研究所 |
Method for improving exogenous gene expression efficiency
|
BR112022011803A2
(en)
|
2019-12-20 |
2022-08-30 |
Curevac Ag |
LIPID NANOPARTICLES FOR NUCLEIC ACIDS DELIVERY
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
IL293571A
(en)
|
2020-02-04 |
2022-08-01 |
Curevac Ag |
Coronavirus vaccine
|
IL294771A
(en)
*
|
2020-02-11 |
2022-09-01 |
Pantherna Therapeutics Gmbh |
Recombinant nucleic acid construct and use thereof
|
EP3865579A1
(en)
*
|
2020-02-12 |
2021-08-18 |
Pantherna Therapeutics GmbH |
Recombinant nucleic acid construct and use thereof
|
CN111218458B
(en)
*
|
2020-02-27 |
2020-11-20 |
珠海丽凡达生物技术有限公司 |
mRNAs encoding SARS-CoV-2 virus antigen and vaccine and preparation method of vaccine
|
CN111118018B
(en)
*
|
2020-03-05 |
2021-06-01 |
泰州博莱得利生物科技有限公司 |
Cat serum albumin recombinant protein and expression method thereof in pichia pastoris
|
AU2021254312B2
(en)
|
2020-04-09 |
2024-01-11 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid nanoparticle composition
|
TW202204622A
(en)
|
2020-04-09 |
2022-02-01 |
大陸商蘇州艾博生物科技有限公司 |
Nucleic acid vaccines for coronavirus
|
AU2021279312A1
(en)
|
2020-05-29 |
2022-12-15 |
CureVac SE |
Nucleic acid based combination vaccines
|
KR20230030588A
(en)
|
2020-06-30 |
2023-03-06 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
Lipid Compounds and Lipid Nanoparticle Compositions
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
KR20230054672A
(en)
|
2020-08-20 |
2023-04-25 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
Lipid Compounds and Lipid Nanoparticle Compositions
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
EP4267178A1
(en)
|
2020-12-22 |
2023-11-01 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
CN112662673B
(en)
*
|
2021-01-08 |
2022-06-28 |
石河子大学 |
Human KLF7 gene promoter as well as construction method and application thereof
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
CN117377491A
(en)
|
2021-03-26 |
2024-01-09 |
葛兰素史克生物有限公司 |
Immunogenic compositions
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
CN113174427B
(en)
*
|
2021-04-29 |
2023-02-28 |
遵义医科大学 |
Method for detecting ERGIC3 mRNA based on DNA molecule
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
AU2022281746A1
(en)
|
2021-05-24 |
2023-09-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
AU2022284878A1
(en)
|
2021-06-04 |
2024-01-18 |
Translate Bio, Inc. |
Assay for quantitative assessment of mrna capping efficiency
|
CN113801213B
(en)
*
|
2021-06-23 |
2022-04-08 |
广东省农业科学院水稻研究所 |
Meloidogyne graminifolia transcription factor MgBTF3 and application thereof in disease control
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
WO2023031392A2
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
CA3230031A1
(en)
|
2021-09-03 |
2023-03-09 |
Patrick Baumhof |
Novel lipid nanoparticles for delivery of nucleic acids
|
WO2023044333A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
AR127312A1
(en)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
|
CN116064598B
(en)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
Nucleic acid vaccine for coronavirus
|
CA3234127A1
(en)
|
2021-10-08 |
2023-04-13 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
KR20230083893A
(en)
*
|
2021-12-03 |
2023-06-12 |
고려대학교 산학협력단 |
5'-UTR with improved translation efficiency, a synthetic nucleic acid molecule comprising the same, and a vaccine or therapeutic composition comprising the same
|
WO2023133525A1
(en)
*
|
2022-01-07 |
2023-07-13 |
Precision Biosciences, Inc. |
Optimized polynucleotides for protein expression
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
CN114645029A
(en)
*
|
2022-03-11 |
2022-06-21 |
上海交通大学 |
Separation of artificially synthesized MpgS protein polypeptide and MpgP protein polypeptide and application thereof
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2024037578A1
(en)
|
2022-08-18 |
2024-02-22 |
Suzhou Abogen Biosciences Co., Ltd. |
Composition of lipid nanoparticles
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
CN117517657B
(en)
*
|
2024-01-08 |
2024-04-09 |
中国农业科学院北京畜牧兽医研究所 |
Application of LNX1 gene or protein in regulation of avian innate immune response
|